Spojené státy - angličtina - NLM (National Library of Medicine)

c.b. fleet company, inc. - sodium phosphate, dibasic, heptahydrate (unii: 70wt22sf4b) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), sodium phosphate, monobasic (unii: 3980jih2sw) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37) - sodium phosphate, dibasic, heptahydrate 2.7 g in 45 ml - - relief of occasional constipation - to help clean out the bowel before medical procedures - under a doctor's care for any medical condition - on a low salt diet ask a doctor or pharmacist before use if you are taking any other prescription or non-prescription drugs. ask a doctor before using any laxative if you have - abdominal (belly) pain, nausea, or vomitting - a change in your daily bowel movements that lasts more than 2 weeks - already used another laxative daily for constipation for more than 1 week - have any rectal bleeding - do not have a bowel movement within 6 hours of taking this product - have any symptoms that your body is losing more fluids than you are drinking. this is called dehydration. early symptoms of dehydration include - feeling thristy - dizziness - urinating less often than normal - vomiting these symptoms may be signs of serious problems.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - prednisolone sodium phosphate, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: sodium hydroxide; sodium chloride; monobasic sodium phosphate; disodium edetate; purified water - non-infected inflammatory conditions of the eye.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydrocortisone hydrogen succinate, quantity: 127.6 mg (equivalent: hydrocortisone, qty 100 mg) - injection, powder for - excipient ingredients: sodium hydroxide; monobasic sodium phosphate monohydrate; dibasic sodium phosphate - when oral therapy is not feasible, and the strength, form and route of administration of the drug ,reasonably lend the preparation to the treatment of the condition, hydrocortisone powder for ,injection is indicated for intravenous or intramuscular use in the following conditions:,1. endocrine disorders,? primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplements may be necessary, particularly when synthetic analogues are used).,? preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful,? shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected,? congenital adrenal hyperplasia,? nonsuppurative thyroiditis,? hypercalcaemia associated with cancer.,2. rheumatic disorders,as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:,? post-traumatic osteoarthritis,? synovitis of osteoarthritis,? rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may ,require low dose maintenance therapy),? acute and subacute bursitis,? epicondylitis,? acute nonspecific tenosynovitis,? acute gouty arthritis,? psoriatic arthritis,? ankylosing spondylitis.,3. collagen diseases,during an exacerbation or as maintenance therapy in selected cases of:,? systemic lupus erythematosus,? systemic dermatomyositis (polymyositis),? acute rheumatic carditis.,4. dermatological diseases,? pemphigus,? severe erythema multiforme (stevens-johnson syndrome),? exfoliative dermatitis,? bullous dermatitis herpetiformis,? severe seborrhoeic dermatitis,? severe psoriasis,? mycosis fungoides.,5. allergic states,control of severe or incapacitating allergic conditions intractable to adequate trials of ,conventional treatment in:,? bronchial asthma,? drug hypersensitivity reactions,? contact dermatitis,? urticarial transfusion reactions,? atopic dermatitis,? serum sickness,? acute noninfectious laryngeal oedema (adrenaline is the drug of first choice).,6. ophthalmic diseases,severe acute and chronic allergic and inflammatory processes involving the eye, such as:,? herpes zoster ophthalmicus,? iritis, iridocyclitis,? chorioretinitis,? diffuse posterior uveitis and choroiditis,? optic neuritis,? sympathetic ophthalmia,? anterior segment inflammation,? allergic conjunctivitis,? allergic corneal marginal ulcers,? keratitis.,7. gastrointestinal diseases,to tide the patient over a critical period of the disease in:,? ulcerative colitis (systemic therapy),? regional enteritis (systemic therapy).,8. respiratory diseases,? symptomatic sarcoidosis,? loeffler?s syndrome not manageable by other means,? berylliosis,? fulminating or disseminated pulmonary tuberculosis when used concurrently with ,appropriate antituberculous chemotherapy,? aspiration pneumonitis.,9. haematological disorders,? acquired (autoimmune) haemolytic anaemia,? erythroblastopenia (rbc anaemia),? idiopathic thrombocytopenic purpura in adults (iv only; im administration is ,contraindicated),? secondary thrombocytopenia in adults,? congenital (erythroid) hypoplastic anaemia.,10. neoplastic diseases,for palliative management of:,? leukaemias and lymphomas in adults,? acute leukaemia in childhood.,11. oedematous states,? to induce diuresis or remission of proteinuria in the nephrotic syndrome, without ,uraemia, of the idiopathic type or that due to lupus erythematosus.,12. miscellaneous,? tuberculous meningitis with subarachnoid block or impending block when used ,concurrently with appropriate antituberculous chemotherapy,? trichinosis with neurological or myocardial involvement.

Keňa - angličtina - Pharmacy and Poisons Board

nabiqasim industries (pvt). ltd. 5th floor commerce centre hasrat mohani road - monobasic sodium phosphate + dibasic sodium… - enema - monobasic sodium phosphate 19.2g + dibasic sodium… - drugs for constipation: osmotically acting

Spojené státy - angličtina - NLM (National Library of Medicine)

beach products, inc. - potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr, potassium cation - unii:295o53k152), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37) - potassium phosphate, monobasic 305 mg - this product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.

Spojené státy - angličtina - NLM (National Library of Medicine)

a-s medication solutions - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone sodium phosphate oral solution is indicated in the following conditions: systemic fungal infections. hypersensitivity to the drug or any of its components.

Spojené státy - angličtina - NLM (National Library of Medicine)

akorn - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 5 mg in 5 ml - prednisolone sodium phosphate oral solution is indicated in the following conditions: systemic fungal infections. hypersensitivity to the drug or any of its components.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prednisolone sodium phosphate, quantity: 6.72 mg/ml (equivalent: prednisolone, qty 5 mg/ml) - oral liquid, solution - excipient ingredients: disodium edetate; dibasic sodium phosphate; propyl hydroxybenzoate; sorbitol solution (70 per cent) (non-crystallising); methyl hydroxybenzoate; purified water; monobasic sodium phosphate; flavour - wherever corticosteroid therapy is indicated.

Kanada - angličtina - Health Canada

pharmascience inc - sodium phosphate monobasic; sodium phosphate dibasic - solution - 480mg; 180mg - sodium phosphate monobasic 480mg; sodium phosphate dibasic 180mg - cathartics and laxatives

Kanada - angličtina - Health Canada

euro-pharm international canada inc - sodium phosphate monobasic; sodium phosphate dibasic, heptahydrate - solution - 0.48g; 0.18g - sodium phosphate monobasic 0.48g; sodium phosphate dibasic, heptahydrate 0.18g - cathartics and laxatives